Incyte, Hemab Look to Shift Von Willebrand Standard Of Care
The two companies presented data for latarcibart and HMB-002, respectively, at the ISTH meeting in Paris.
Scrip - July 13, 2026

HistoSonics Receives CE Mark For Liver Tumor-Fighting Non-Invasive Histotripsy Tech
HistoSonics received a CE mark for its non-invasive Edison Histotripsy System to destroy liver tumors, backed by #HOPE4LIVER trial data showing 95% technical success and a 7% major complication rate.
Medtech Insight - July 13, 2026

In Separate Warning Letters, FDA Cites Firms Over Disinfection Devices And Device Marketing Claims
In two recent warning letters, the FDA cited a Michigan manufacturer for marketing disinfection devices without required premarket authorization and a Tennessee firm for promoting its eyelid cleaning device for unapproved uses and for significant quality system violations.
Medtech Insight - July 13, 2026

Q32 Will Advance JAK Alternative For Alopecia To Phase III
Strong Phase II data showed the IL-7R? antibody bempikibart was effective in alopecia areata. The company’s stock price jumped 63% in early trading on the news.
Scrip - July 13, 2026

Eli Lilly’s Blood Test Pioneer Is Focused On Accelerating Alzheimer’s Drug Development
Oskar Hansson established the use of the P-tau217 blood-based test for Alzheimer’s and now heads up Lilly’s neurodegeneration discovery and early clinical trials. He tells Scrip how blood-based diagnostics could help transform drug development in the field.
Scrip - July 13, 2026

Novo Doubles Down On Denecimig Ahead Of FDA D-Day
The Danish firm is hoping to challenge the dominance of Roche's blockbuster Hemlibra for hemophilia A with or without inhibitors.
Scrip - July 13, 2026

Who’s Hired? Sandoz’s Fromm Switches To Accord
As a longtime Sandoz executive switches to Accord Healthcare, new appointments have also been announced at Biosimilars Canada, Medicines For Europe, Stada, Rezon Bio, Pfizer And Pharmanovia.
Generics Bulletin - July 13, 2026

Tariffs Meant To Reshore Medtech Would Send It Offshore, Industry Tells USTR
Medtech manufacturers, hospitals and EU trade bodies are pressing USTR to exempt medical devices from proposed Section 301 forced-labor tariffs, warning the levies would raise healthcare costs, disrupt fragile supply chains, and push production offshore rather than reshore it.
Medtech Insight - July 13, 2026

Clean FDA Review Sharpens NRx Ketamine Commercial Case
NRx says FDA reviewers have raised no major issues with its preservative-free ketamine ANDA, as the company prepares for a potential third-quarter decision and continues manufacturing and financing work ahead of launch.
Generics Bulletin - July 13, 2026

People On The Move: Appointments At Stada, Opella And NèreS
A round up of the latest moves in Europe's consumer health sector: Stada hires Reckitt's Mark Pearson to lead global consumer healthcare; Opella names Nikhilesh Kalra as Western Europe general manager; NèreS elects Haleon's Céline Camilleri as president.
HBW Insight - July 13, 2026

Pipeline Watch: Two Approvals And Six Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - July 13, 2026

Ennumo Approval Gives Accord Two-Pronged Pegfilgrastim Strategy
FDA approval of Ennumo gives Accord a second US pegfilgrastim biosimilar, broadening its G-CSF offering and reinforcing the company’s push to build a 20-product biosimilars portfolio by 2030.
Generics Bulletin - July 13, 2026

Obesity’s Marketing Playbook Is Colliding With Europe’s Advertising Red Lines
France’s ANSM fined Novo Nordisk and Eli Lilly over obesity “awareness” campaigns it says crossed into banned direct-to-consumer promotion. With probes opening across Europe and fines dwarfed by drug revenue, the test is whether enforcement can keep pace with the gold rush.
In Vivo - July 13, 2026